Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

10 minutes ago
1 min read

CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.

https://vimeo.com/1169793020

Recent Posts

See All

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight